Amifostine for Head and Neck Irradiation in Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma
In brief
The purpose of this study is determine the effects (good and bad) amifostine has on radiation-induced side effects of lymphoma treatment.
Key facts
- Study ID
- NCT00136474
- Run by
- Dana-Farber Cancer Institute
- People needed
- 75
- Starts
- 2003-05-01
- Expected to finish
- 2009-03-01
- Last updated by the study team
- 2009-11-02
Who can join
Age: 35 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must be 35 years or older
- Histologically confirmed Hodgkin's disease or non-Hodgkin's lymphoma receiving radiation therapy to the head and neck area.
- Involvement of one or more of the following sites: cervical node, supraclavicular node, pre-auricular node, submental node, any salivary glands, any parts of the oral cavity, or any parts of the oropharynx.
You may not qualify if…
- Prior history of head and neck malignancies
- Prior radiation therapy to the head and neck region
- Patients with stage I Hodgkin's disease receiving radiation therapy alone
- Pregnant or lactating women
- Myocardial infarction within the 6 months of enrollment
- Clinically evident pulmonary insufficiency, except for patients with exertional dyspnea related to chest tumor itself.
Where it is running
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.